Background
==========

According to July 2009 estimates, 69% of the cocaine seized by the US Drug Enforcement Administration (DEA) is adulterated with levamisole \[[@B1],[@B2]\]. Levamisole is a veterinary antihelminthic agent that has recently been linked to vasculitis and neutropenia in people with cocaine use \[[@B3],[@B4]\]. We describe a cocaine user with levamisole-induced necrosis of the skin, soft tissue, and cartilage resulting in nasal amputation, earlobe necrosis, and bilateral above-knee amputation (AKA). To the best of our knowledge, this is only the second case of levamisole-induced vasculitis requiring above-knee amputation to be reported in the English language literature, and it is also one of the first reported cases with laboratory confirmation of levamisole exposure.

Case presentation
-----------------

A 44-year-old African American woman with history of hypertension and asthma presented to the hospital with a complaint of a painful rash on her extremities of 2-3 months' duration. The rash first appeared on her upper extremities and then progressed to her legs, cheeks, nose, and earlobes. She denied a history of fever, weight loss, alopecia, dry mouth, oral ulcers, painful red eyes, photosensitivity, myalgia, arthralgia, joint swelling, dysphagia, miscarriages, or blood clots. The patient had a chronic history of crack cocaine use and a smoking history of five pack-years. On examination, her vital signs were stable. Skin examination revealed erythematous maculopapular purpuric lesions on her nose, cheeks, and earlobes with central blackish discoloration (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). She had several large violaceous plaques and flaccid bullae on her upper and lower extremities and a stage-II ulcer on the medial surface of her right ankle with some serosanginuous discharge. Other physical examination results were normal.

![Purpuric lesions and necrosis of both earlobes.](1940-0640-7-19-1){#F1}

![Purpuric patches on extremities.](1940-0640-7-19-2){#F2}

Laboratory investigations revealed leukopenia with a white blood cell count (WBC) of 2,600 cells/μL, neutropenia with an absolute neutrophil count (ANC) of 900 cells/μL, an elevated erythrocyte sedimentation rate (ESR) of 47 mm/hour, presence of lupus anticoagulant, low complement component 3 (C3) (85 mg/dL), a normal coagulation profile, absence of antinuclear antibody (ANA), absence of cardiolipin antibody, presence of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) against myeloperoxidase (MPO), and absence of antiproteinase 3 (anti-PR3) antibody.

Her urine toxicology screen was positive for cocaine, and gas chromatography--mass spectrometry (GCMS) was positive for levamisole. Punch biopsy of the skin from involved areas showed leukocytoclastic vasculitis with angiocentric infiltrates of mixed inflammatory cells and small vessel thrombosis with multiple fibrin thrombi in the lumen of the vessels (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

![Hematoxylin & eosin staining of skin biopsy sample showing leuckocytoclastic vasculitis with angiocentric infiltrates of mixed inflammatory cells (white arrow) and small vessel thrombosis.](1940-0640-7-19-3){#F3}

![**Leukocytoclastic vasculitis.** A dermal small vessel showing a neutrophilic-rich infiltrate with karyorrhexis and extravasated erythrocytes within the vessel wall and adjacent tissue. Intra-luminal fibrin thrombi are also present.](1940-0640-7-19-4){#F4}

Lesions on the lower extremities continued to expand, and those on nose, left cheek, and ears became necrotic. Large lower extremity bullae ruptured, leading to wound infection and septicemia with *Staphylococcus aureus*, *Enterobacter cloacae,* and *Morganella morganii,* which were treated with broad-spectrum antibiotics. At this point, skin involvement was estimated to be 35% of the total body surface area, and the patient was managed in a burn unit. Extensive and infected necrosis of the lower extremities required fascial excision of the dead skin and subcutaneous tissue. The patient underwent two further surgical debridements. Despite this, necrosis progressed, and attempts at nonoperative management were not successful. Eventually, bilateral AKA of the legs above the areas of necrotic skin was performed to control the spread of nonhealing necrotic wounds. The decision to proceed with bilateral AKA was based on the presence of a significant degree of necrosis of leg muscles and the poor functional prognosis for the lower extremities, even if the nonhealing wounds eventually closed with local wound care or skin grafts. Necrotic lesions on the nose led to its self-amputation (Figure [5](#F5){ref-type="fig"}). The patient's pain was controlled with morphine (patient controlled analgesia). New lesions stopped appearing a few days following surgery, and she was discharged home with a prescription of gabapentin for neuropathic pain.

![Necrotic lesions on the nose that eventually led to nasal septal destruction and self-amputation.](1940-0640-7-19-5){#F5}

Two months later, the patient was readmitted with new painful necrotic lesions on the amputated stumps (Figure [6](#F6){ref-type="fig"}). She admitted to cocaine use three days prior to this admission. She was treated with intravenous methylprednisolone for three days followed by tapering doses of oral prednisone for seven days. Her pain and lesions improved significantly, and she was discharged home with a plan to follow up with the hospital's plastic surgery service for nose reconstruction.

![Recurrent purpuric and necrotic lesions on the amputation stumps with repeat use of cocaine.](1940-0640-7-19-6){#F6}

Discussion
==========

Levamisole is a veterinary antihelminthic agent currently used to treat worm infestations in cattle, sheep, and pigs \[[@B5]\]. In the past, it was used in humans to treat various autoimmune disorders and cancers because of its immunomodulatory properties \[[@B5]\]. Levamisole-induced vasculitis (LIV) was first reported in a rheumatoid arthritis patient in 1978 \[[@B6]\]. Since 2009, levamisole has also been linked to cutaneous vasculitis in people who use cocaine.

To the best of our best knowledge, 32 cases of LIV in patients with cocaine use have been reported to date \[[@B3],[@B4],[@B7]-[@B22]\]. Clinical features, laboratory results, skin biopsy findings, and the treatment of these patients are summarized in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. Of the 32 patients described, only eight had levamisole exposure confirmed by urinalysis or GCMS, although other authors speculated on this link based on the presence of levamisole in approximately 69% of the cocaine entering the United States. Among all the reported cases, only one (published twice by different authors, i.e., Ching et al. \[[@B15]\] and Mouzakis et al. \[[@B16]\]) had extensive necrosis requiring AKA. The patient was a 54-year-old man positive for p-ANCA who developed fever, agranulocytosis, and extensive skin necrosis following heavy intranasal cocaine use. Necrosis was present on more than 50% of his total body surface area, requiring thorough wound debridement, skin grafting, and left-sided AKA. Unlike our patient, AKA in this case was unilateral, and levamisole exposure was not confirmed by GCMS since the patient presented late after the likely exposure. The authors speculated that levamisole exposure was probable based on the patient's clinical presentation and history of cocaine use. Our patient represents the most extensive confirmed case of LIV with involvement of 35% of her total body surface area.

###### 

Clinical features of all reported cases of levamisole-induced cutaneous vasculitis in patients with cocaine use

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Authors**                       **Age/Sex**                                                                                              **Clinical findings**
  --------------------------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Gross RL et al. \[[@B3]\]         50 years/M                                                                                               Retiform pupuric plaques with ulceration on earlobes/helix and lower extremities

  42 years/M                        Reticulate pink/purple erythematous eruptions on legs, chest, arms, and back                             

  42 years/F                        Violaceous papules, reticular-purpuric plaques on arms, breasts, legs, and ears                          

  59 years/F                        Purpuric, necrotic plaques and bullae on face, ears, arms, right cheek, chest, and axilla                

  Ullrich K et al. \[[@B4]\]        45 years/M                                                                                               Painful necrotic purpura and skin nodules on extremities and ears

  49 years/F                        Painful purpura on extremities, trunk, and earlobes                                                      

  27 years/F                        Painful purpura on lower extremities, arthralgia                                                         

  29 years/F                        Purpuric lesion with central necrosis on left foot, purpuric lesions on both ears                        

  55 years/F                        Episodic rash on face, trunk, and extremities                                                            

  Bradford M et al. \[[@B7]\]       57 years/F                                                                                               Purpuric plaques with central necrosis on cheeks and earlobes

  22 years/F                        Erythematous plaques with central necrosis on face, ears, legs, thighs, and buttocks                     

  Buchanan JA et al. \[[@B8]\]      Not specified/M                                                                                          Purple discoloration on left upper arm and right second toe, bilateral necrosis of ears

  Walsh NMG et al. \[[@B9]\]        39 years/F                                                                                               Retiform purpura, hemorrhagic bullae on legs, trunks, and buttocks

  49 years/F                        Retiform purpura on chest, limbs, bilateral nasal mucosal ulcers                                         

  Waller JM et al. \[[@B10]\]       38 years/F                                                                                               Retiform purpura with central necrosis on earlobes, cheeks, breast, extremities

  43 years/F                        Retiform purpura with central necrosis on legs, arms, and pinna; livedo racemosa, splinter hemorrhages   

  Farhat EK et al. \[[@B11]\]       43 years/F                                                                                               Retiform purpura with central necrosis on bilateral lower extremities

  41 years/F                        Painful retiform purpuric patches on thighs, buttocks, trunk, upper extremities, and nasal tip           

  Click J \[[@B12]\]                29 years/F                                                                                               Calf ulcerations, retiform purpura

  Geller L et al. \[[@B13]\]        50 years/F                                                                                               Stellate purpura with central necrosis on upper extremities, ears, back, and breasts

  Han C et al. \[[@B14]\]           52 years/F                                                                                               Painful retiform purpura with ulceration on arms, legs, nasal tip, cheeks, ears

  Ching J et al. \[[@B15]\]/\       54 years/F                                                                                               Purpuric patches and plaques on legs, upper extremities, perinasal area, anterior trunk, face, and ears
  Mouzakis J et al. \[[@B16]\]                                                                                                               

  Jacob RS et al. \[[@B17]\]        41 years/F                                                                                               Tender purpuric patches and plaques on ears, legs, upper extremities, back, toes, and soles

  48 years/F                        Tender purpuric patches and plaques on ears and left cheek                                               

  Lung D et al. \[[@B18]\]          44 years/F                                                                                               Stellate, purpuric macules and plaques with central necrosis on legs, abdomen, and face

  Zwang NA et al. \[[@B19]\]        52 years/M                                                                                               Violaceous retiform papules/plaques on arms, legs, back, trunk, scalp, buttocks, fingers, foot, and ear

  Chung C et al. \[[@B20]\]         46 years/F                                                                                               Purpura and necrosis on bilateral ears, cheeks, and upper and lower extremities

  46 years/F                        Bilateral ear necrosis, diffuse retiform purpura with necrosis on neck, trunk, and extremities           

  37 years/M                        Tender bilateral ear purpura and necrosis, diffuse retiform purpura on trunk and extremities             

  50 years/M                        Tender purpura and necrosis on both ears, purpura and bullae on trunk and extremities                    

  Jenkins J et al. \[[@B21]\]       47 years/M                                                                                               Painful retiform purpura with necrotic center on legs, ears, cheek, tongue, trunk, and genitalia

  John S et al. \[[@B22]\]          52 years/F                                                                                               Painful violaceous plaques and flaccid bullae on right ankle, legs, left arm, and left breast

  Arora et al. \[current report\]   44 years/F                                                                                               Erythematous purpuric lesions with central necrosis on nose, cheeks, earlobes, and extremities
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Laboratory findings of all reported cases of levamisole-induced cutaneous vasculitis in patients with cocaine use

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Authors**                       **Age/Sex**                           **Leucopenia and/or Neutropenia**                    **Antibodies present**
  --------------------------------- ------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  Gross RL et al. \[[@B3]\]         50 years/M                            Yes, WBC -3,300/μL, ANC -2400/μL                     p-ANCA, ANA, LAC, c-ANCA, anti-ds-DNA

  42 years/M                        Yes, WBC -3,200/μL, ANC - 800/μL      p-ANCA, ANA, LAC, c-ANCA, IgM ACL                    

  42 years/F                        No                                    p-ANCA, c-ANCA, ANA                                  

  59 years/F                        No                                    p-ANCA, ANA, anti-RNP                                

  Ullrich K et al. \[[@B4]\]        45 years/M                            Yes, WBC -1,900/μL, ANC -1,000/μL                    p-ANCA, c-ANCA, ANA, IgM ACL

  49 years/F                        Yes, WBC -3,500/μL, ANC -- 0 (zero)   ANA, c-ANCA                                          

  27 years/F                        Yes, WBC -1,800/μL, ANC -400/μL       p-ANCA, c-ANCA, IgM ACL, ANA                         

  29 years/F                        No                                    p-ANCA, c-ANCA, IgM ACL, ANA                         

  55 years/F                        Yes, WBC -3,700/μL, ANC -2,300/μL     p-ANCA, c-ANCA, IgM ACL                              

  Bradford M et al. \[[@B7]\]       57 years/F                            Yes, ANC -500/μL                                     p-ANCA, IgM ACL

  22 years/F                        Yes, ANC \< 1,000/μL                  p-ANCA, IgM ACL                                      

  Buchanan JA et al. \[[@B8]\]      Not specified/M                       Yes, WBC -1,900/μL                                   Not reported

  Walsh NMG et al. \[[@B9]\]        39 years/F                            No                                                   p-ANCA, c-ANCA, ANA, LAC, anti-HNE

  49 years/F                        Yes, WBC -2,000/μL, ANC -400/μL       p-ANCA, c-ANCA, ANA, anti-HNE                        

  Waller JM et al. \[[@B10]\]       38 years/F                            Yes, ANC -550/μL                                     p-ANCA, c-ANCA, LAC

  43 years/F                        Yes, ANC -560/μL                      p-ANCA, IgM ACL, LAC, anti-ds-DNA,                   

  Farhat EK et al. \[[@B11]\]       43 years/F                            No                                                   p-ANCA

  41 years/F                        No                                    p-ANCA, IgM ACL                                      

  Click J \[[@B12]\]                29 years/F                            No                                                   p-ANCA, c-ANCA, ANA

  Geller L et al. \[[@B13]\]        50 years/F                            Yes, WBC -2,700/μL, ANC -1,400/μL                    p-ANCA, IgM ACL

  Han C et al. \[[@B14]\]           52 years/F                            Yes, WBC -2,400/μL, ANC -1,400/μL                    p-ANCA, c-ANCA, IgM ACL

  Ching J et al. \[[@B15]\]/\       54 years/F                            Yes, WBC -3,900/μL, ANC -300/μL                      p-ANCA, IgM ACL
  Mouzakis J et al. \[[@B16]\]                                                                                                 

  Jacob RS et al. \[[@B17]\]        41 years/F                            Yes, WBC -1,100/μL, ANC -670/μL                      p-ANCA, c-ANCA, IgM ACL, ANA, anti-ds-DNA,anti-HNE

  48 years/F                        Yes, WBC -800/μL, ANC -300/μL         p-ANCA, c-ANCA, IgM ACL, ANA, anti-ds-DNA,anti-HNE   

  Lung D et al. \[[@B18]\]          44 years/F                            Yes, ANC -270/μL                                     Not reported

  Zwang NA et al. \[[@B19]\]        52 years/M                            No                                                   p-ANCA, c-ANCA, IgM ACL, ANA, LAC, anti-HNE,\
                                                                                                                               anti-ds-DNA,

  Chung C et al. \[[@B20]\]         46 years/F                            No                                                   p-ANCA, c-ANCA, IgM ACL

  46 years/F                        Yes, WBC and ANC not specified        p-ANCA, c-ANCA, IgM ACL                              

  37 years/M                        No                                    p-ANCA, ANA                                          

  50 years/M                        No                                    p-ANCA, ANA                                          

  Jenkins J et al. \[[@B21]\]       47 years/M                            No                                                   p-ANCA

  John S et al. \[[@B22]\]          52 years/F                            Yes, WBC -2,900/μL, ANC -638/μL                      p-ANCA +,\
                                                                                                                               anti ds-DNA+

  Arora et al. \[current report\]   44 years/F                            Yes, WBC -2,600/μL, ANC -900/μL                      p-ANCA+, LAC+
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: *M* = male, *F* = female, *WBC* = white blood cell count, *ANC* = absolute neutrophil count, *p-ANCA* = perinuclear anti-neutrophil cytoplasmic antibody, *c-ANCA* = cytoplasmic anti-neutrophil cytoplasmic antibody, *IgM ACL* = immunoglobulin-M anticardiolipin antibody, *ANA* = antinuclear antibody, *LAC* = lupus anti-coagulant, anti-*HNE* = anti-human neutrophil elastase antibody, anti-*ds-DNA* = anti-double-stranded deoxyribonucleic acid antibody, anti-*RNP* = anti-ribonucleoprotein antibody.

###### 

Skin biopsy findings, treatment, and response to treatment information of all reported cases of levamisole-induced cutaneous vasculitis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Authors**                       **Age/Sex**                                                          **Pathology**                                                          **Treatment**                                                                                   **Response**
  --------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  Gross RL et al. \[[@B3]\]         50 years/M                                                           Vasculitis, thrombosis, necrosis                                       Oral prednisone, surgical debridement                                                           Lesions remained stable, developed auditory hallucinations & superinfection

  42 years/M                        Small-vessel vasculitis                                              Supportive care                                                        Lesions improved without any intervention                                                       

  42 years/F                        Lekocytoclastic vasculitis, thrombosis                               Oral prednisone                                                        Lesions improved in one week                                                                    

  59 years/F                        Small-vessel vasculitis, thrombosis                                  Oral prednisone                                                        Lost to follow-up                                                                               

  Ullrich K et al. \[[@B4]\]        45 years/M                                                           Not reported                                                           Oral prednisone                                                                                 Initially improved, but symptoms recurred with attempts to taper the steroid dose

  49 years/F                        Thrombosis, perivascular neutrophils, and karyorrhetic debris        Supportive, G-CSF                                                      Resolution of lesions with abstinence from cocaine                                              

  27 years/F                        Lekocytoclastic vasculitis, thrombosis                               Oral prednisone                                                        Lesions resolved with abstinence, arthralgia and neutropenia improved rapidly with prednisone   

  29 years/F                        Not reported                                                         Supportive care, oral steroids                                         Lesions resolved with abstinence, septal perforation & arthralia improved with steroids         

  55 years/F                        Lekocytoclastic vascultis, thrombosis                                Steroids, cyclophosphamide                                             Rapid resolution of lesions                                                                     

  Bradford M et al. \[[@B7]\]       57 years/F                                                           Intravascular thrombosis, no vasculitis                                Filgrastim for neutropenia                                                                      Lesions resolved spontaneously, neutropenia improved with filgrastim

  22 years/F                        Leucocytoclastic vasculitis, thrombosis                              Steroids                                                               Lesions and neutropenia improved rapidly                                                        

  Buchanan JA et al. \[[@B8]\]      Not specified/M                                                      Not done                                                               Subcutaneous phentolamine to both ears                                                          No improvement

  Walsh NMG et al. \[[@B9]\]        39 years/F                                                           Thrombosis, leucocytoclastic vasculitis                                Anticoagulation, skin debridement and grafting                                                  No new lesions with discontinuation of cocaine, skin lesions healed after multiple full thickness skin grafts

  49 years/F                        Thrombosis, no evidence of vasculitis                                Supportive care                                                        Lesions improved, recurrences with cocaine use                                                  

  Waller JM et al. \[[@B10]\]       38 years/F                                                           Leukocytoclastic vasculitis, thrombosis                                Supportive care                                                                                 Lesions improved, recurrences with cocaine use

  43 years/F                        Thrombosis of dermal vessels                                         Supportive care                                                        Lesions improved, recurrences with cocaine use                                                  

  Farhat EK et al. \[[@B11]\]       43 years/F                                                           Extensive thrombosis, no vasculitis                                    Supportive care                                                                                 Not specified

  41 years/F                        Thrombosis with no vasculitis                                        Not specified                                                          Not specified                                                                                   

  Click J \[[@B12]\]                29 years/F                                                           Subepidermal bullous dermatitis, lymphocytic perivascular infiltrate   Skin grafts                                                                                     Lesions were healing well after 4 months

  Geller L et al. \[[@B13]\]        50 years/F                                                           Lecocytoclastic vasculitis, thrombosis                                 Not specified                                                                                   Not specified

  Han C et al. \[[@B14]\]           52 years/F                                                           Thrombotic vasculopathy, no vasculitis                                 Steroids (iv & oral), dalteparin, warfarin                                                      Lesions and neutropenia improved, had recurrences in with repeat cocaine use, which improved with oral prednisone

  Ching J et al. \[[@B15]\]/\       54 years/F                                                           Small vessel thrombosis, perivascular mononuclear infiltrates          IV steroids, left AKA, skin debridement, allografts                                             Developed extensive skin necrosis requiring debridement and skin grafts
  Mouzakis J et al. \[[@B16]\]                                                                                                                                                                                                                                                  

  Jacob RS et al. \[[@B17]\]        41 years/F                                                           Epidermal necrosis, vascular thrombosis, leukocytoclasis               Oral prednisone                                                                                 Resolution of the majority of the patient's lesions

  48 years/F                        Lymphocytic infiltrate, occlusive vasculopathy, neovascularization   Oral prednisone                                                        Lesions improved                                                                                

  Lung D et al. \[[@B18]\]          44 years/F                                                           Extensive thrombotic vasculopathy                                      Not specified                                                                                   Not specified

  Zwang NA et al. \[[@B19]\]        52 years/M                                                           Leukocytoclastic vasculitis                                            Oral prednisone                                                                                 Lesions healed completely in 3 weeks

  Chung C et al. \[[@B20]\]         46 years/F                                                           Small-vessel vascultits with thrombosis                                Steroids                                                                                        Initial improvement, lost to follow-up

  46 years/F                        Multiple Intravascular thrombi                                       IV methyl-prednisolone                                                 Gradual improvement initially, lost to follow-up                                                

  37 years/M                        Leucocytoclastic vasculitis                                          Supportive                                                             Rapid improvement of skin lesions                                                               

  50 years/M                        Leucocytoclastic vasculitis, panniculitis                            Supportive, antibiotics                                                Rapid improvement of skin lesions                                                               

  Jenkins J et al. \[[@B21]\]       47 years/M                                                           Leucocytoclastic vascultits, occlusive vasculopathy                    Oral & topical steroids, aspirin, pentoxifylline                                                Lesions resolved over 3 months

  John S et al. \[[@B22]\]          52 years/F                                                           Thrombotic vasculopathy, no vasculitis                                 Supportive, surgical debridement                                                                Had new lesions with repeat cocaine use and necrotic ulceration of old lesions requiring surgical debridement

  Arora et al. \[current report\]   44 years/F                                                           Leucocytoclastic vasculitis, thrombosis                                Surgical debridement, pain control, AKA, IV methyl-prednisolone for recurrent lesions           Recurrent lesions improved significantly with IV methylprednisolone
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: *M* = male, *F* = female, *AKA* = above knee amputation, *IV* = intravenous.

Levamisole was an FDA-approved drug but was withdrawn for use in humans in the USA in 1999 due to reports of serious adverse effects such as agranulocytosis, thrombocytopenia, arthritis, and LIV \[[@B23]-[@B26]\]. However, it is still available for animal use in the United States, Canada, and South America \[[@B26]\]. In the presence of alternative and more efficacious veterinary antihelminthics, such as ivermectin \[[@B27],[@B28]\], the reasons for continued availability of levamisole for animal use are poorly understood, especially in light of the emerging data on the potential dangers of its addition to cocaine.

The practice of adulterating cocaine with levamisole has increased significantly in recent years \[[@B26],[@B29]\]. Several theories exist to explain the reasons for adulterating cocaine with levamisole. One explanation may be levamisole's ability to potentiate the psychotropic effects of cocaine \[[@B26]\]. Stimulant effects of cocaine are mediated by the blockage of presynaptic reuptake pumps for the monoamine neurotransmitters dopamine, norepinephrine, and serotonin in the central and peripheral nervous systems leading to their enhanced activity \[[@B30],[@B31]\]. Animal data suggest that levamisole may have an inhibitory action on monoamine oxidase and catechol-O-methyltransferase, the enzymes that metabolize catecholamine neurotransmitters \[[@B26]\]. Therefore, levamisole may potentially inhibit the degradation of these stimulatory neurotransmitters, prolonging the duration of their action and adding to the reuptake-inhibition effect of cocaine. Clinically, this may result in enhanced psychotropic effects \[[@B26]\]. Antihelminthic properties of levamisole are due to its species-specific agonistic action at nicotinic acetylcholine receptors of the muscle cells of nematodes \[[@B32]\]. Cocaine may also act on the nicotinic acetylcholine receptors of humans, resulting in increased dopaminergic reuptake inhibition and glutamatergic activity \[[@B33]\]. Although unlikely due to species-specific action of levamisole, it is theoretically possible that cocaine and levamisole may have a synergistic action at nicotinic acetylcholine receptors resulting in increased nicotinic and dopaminergic effects \[[@B26]\]. Also, studies in horses have suggested that levamisole may get metabolized to aminorex, an amphetamine derivative with stimulant effects similar to cocaine and amphetamine \[[@B34]\]. Other possible explanation for using levamisole as a cocaine adulterant may be its use as a "marker" or "signature" compound by manufacturers to trace its market distribution \[[@B26]\]. Some media reports suggest that levamisole is used as a cutting agent for cocaine because it adds bulk and weight to powdered crack cocaine while retaining the appearance and look of pure cocaine, and it also has the ability to pass cocaine purity tests used by drug dealers. Levamisole-induced cutaneous vasculitis has been reported both with smoked crack cocaine \[[@B17]\] and inhaled powdered cocaine \[[@B21]\], indicating that both are adulterated with levamisole.

In addition to levamisole, other commonly used cocaine adulterants include local anesthetics, sugars, stimulants (such as caffeine, ephedrine, phenylpropanolamine, and amphetamines); toxins (such as quinine and strychnine); and inert compounds \[[@B35]\]. Among these cocaine adulterants, only stimulants have been associated with vasculitis upon chronic use. Unlike LIV, the vasculitis associated with chronic stimulant use is usually cerebral or systemic in distribution \[[@B35]\].

As LIV is usually associated with the generation of autoantibodies such as p-ANCA, ANA, and lupus anticoagulant, it may be difficult to differentiate it from autoimmune disorders such as Wegener's granulomatosis and other small-vessel vasculitides. The exact pathogenic mechanisms responsible for the formation of these autoantibodies remain elusive. Recent reports have suggested that, due to its ability to act as a hapten, levamisole may cause increased formation of antibodies to various antigens and therefore lead to an immune response involving the opsonization and eventual destruction of the leukocytes \[[@B33]\].

Before the recognition of levamisole as an adulterant in the cocaine supply, cocaine alone was associated with an p-ANCA-positive pseudovasculitis in some previous reports \[[@B36]\]. Although clinical presentation and laboratory findings of pseudovasculitis may be similar to true vasculitis, biopsy specimens in pseudovasculitis patients do not reveal the typical histopathologic findings seen in patients with true vasculitis \[[@B36]\]. Moreover, there is a possibility that these cocaine-related pseudovasculitis cases were actually caused by unrecognized contamination with levamisole.

Adulteration of the majority of the cocaine supply entering United States with levamisole is concerning, especially in view of the high frequency of cocaine use in this country. According to the August 2005 National Survey on Drug Use and Health (NSDUH) Report, more than 5.9 million (2.5%) persons aged 12 years or older used cocaine in 2002-2003 \[[@B37]\].

Based on published reports, Levamisole-induced cutaneous vasculitis in cocaine users is more commonly seen in women \[[@B3]\]. Clinical features commonly include a tender purpuric rash in a retiform/reticular distribution with or without necrosis \[[@B3]\]. In addition to leukopenia and neutropenia, laboratory results are usually positive for different types of auto-antibodies such as c-ANCA, p-ANCA, ANA, and lupus anticoagulant \[[@B3]\]. Recurrence or exacerbation of skin lesions with cocaine use have been reported in some cases. Skin biopsy shows either a mixed pattern of leukocytoclastic and thrombotic vasculitis or an isolated thrombotic vasculopathy \[[@B3]\].

Cessation of cocaine use and supportive care of LIV-related skin lesions lead to resolution of symptoms in most of the cases. Steroids have been used in a significant number of previously reported cases with a variable response. The recurrent lesions in our patient improved significantly after intravenous methylprednisolone. However, due to the risk of increased susceptibility to superimposed infections, steroid use should be limited to more severe cases that fail to respond to supportive care. Patients should be educated about the possible adverse effects of future cocaine use. Extensive skin involvement and necrosis may need surgical debridement and skin grafting. As happened in our patient, in extreme cases that involve extensive necrosis, amputation may be required to contain necrosis and infection.

Conclusions
===========

Adulteration of cocaine with levamisole is widely prevalent in United States. Levamisole may cause cutaneous vasculitis and neutropenia in people with cocaine use. History of cocaine use should be explored in patients presenting with a rash and neutropenia, and testing for levamisole exposure should be performed in selected patients. In cases with extensive involvement, this condition may lead to disfigurement by causing necrosis of skin, soft tissue, and cartilage.
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